Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 13/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.40 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16257589 | 0.87 | CSNK2A2 (0.48) | KDM4EEGFRPIM1MAPK1FYN | |
| SCHEMBL16257608 | 0.85 | HPGD (0.47) | KDM4EEGFRERBB2 | |
| SCHEMBL16257609 | 0.84 | CSF1R (0.47) | KDM4EEGFRMAPK1 | |
| SCHEMBL16257513 | 0.82 | CSF1R (0.45) | KDM4EEGFRMAPK1 | |
| SCHEMBL15033668 | 0.78 | KMO (0.58) | EGFRERBB2 | |
| SCHEMBL16257590 | 0.72 | KIT (0.50) | — | |
| SCHEMBL16257511 | 0.72 | DHODH (0.55) | KDM4EEGFRFYNSRC | |
| SCHEMBL14306362 | 0.72 | LMNA (0.58) | EGFRABCG2 | |
| SCHEMBL16257576 | 0.71 | ANO1 (0.49) | EGFRABCG2 | |
| SCHEMBL16257591 | 0.71 | EGFR (0.50) | KDM4EEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946218-B2 | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2569295-B1 | NEW CCR2 RECEPTOR ANTAGONISTS, METHOD FOR PRODUCING THE SAME, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |